{'fraction_non_alphanumeric': 0.02737382378100941, 'fraction_numerical': 0.003421727972626176, 'mean_word_length': 5.157894736842105, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Hypercholesterolemia in ExHC rats and lipid-lowering drug: a screening method for new hypocholesterolemic agents.

The ExHC rat strain which was selected and bred from the Sprague-Dawley strain, develops severe hypercholesterolemia and is liable to aortic lipid deposition when the rats are fed an atherogenic diet. After only 4 days on the atherogenic diet, hypercholesterolemia was induced in these ExHC rats. Following a study of gel-filtration and SDS-disc electrophoresis, significant increases of broad-LDL (beta-VLDL) and of apo E and apo B were noted. On the other hand, plasma HDL and its major apolipoprotein, apo A-I, showed decreases. All these changes might be responsible for the future induction of aortic lipid deposition. A screening method for new hypocholesterolemic agents which takes advantage of these ExHC rat characteristics has been set up; it involves the evaluation of cholesterol lowering and HDL increasing effects by the determination of plasma cholesterol and by radioimmunoassay of apo A-I, respectively. Although clofibrate (100 mg/kg body weight) reduced plasma cholesterol levels significantly, there was no apo A-I increasing effect.